Shenyi capsule is a national class I Chinese medicine monomer anti-tumor vascular targeting Chinese medicine independently developed by Yatai pharmaceutical.It is the first Chinese medicine monomer drug independently developed in China after artemisinin.Shenyi capsule is the only oral tumor antineovascularization inhibitor approved by SFDA in the specification.
In 2014, Shenyi Capsule, a new class I traditional Chinese medicinal monomer, won the second prize of National Scientific and Technological Invention Award in 2013.
In 2017, it was included in the National Health Insurance Directory as one of the first batch of negotiated products, achieving the long-cherished wish of participating in a capsule for 18 years and achieving a new milestone in product launch.
Shenyi capsule is mainly composed of 20 (R) -ginsenoside Rg3 monomer, with a purity of over 95%, molecular formula: C42H72O13, molecular weight of 784.3, which is the first approved oral anti-tumor neovasculature targeting agent in China that was listed in 2000.
Shenyi capsule is into a number of diagnosis and treatment guidelines, clinical diagnosis and treatment guidelines in the first line of drugs.It is a first-line drug of the tenth five-year","
As an antiangiogenic drug, Shenyi capsule has been recommended as the first-line treatment drug byNCCN clinical practice guide for non-small cell lung cancer (Chinese version) for six consecutive years, and recommended as a treatment drug for lung cancer, breast cancer and thyroid cancer by the by the Guidelines for diagnosis and treatment of tumor in traditional Chinese medicine.And it is recommended as a therapeutic drug for lung cancer, esophageal cancer, colorectal cancer and ovarian cancer by the Guidelines for Diagnosis and Treatment of Malignant Tumors in Traditional Chinese Medicine.